<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553226</url>
  </required_header>
  <id_info>
    <org_study_id>01102015</org_study_id>
    <nct_id>NCT02553226</nct_id>
  </id_info>
  <brief_title>Continued Versus Discontinued Oxytocin Stimulation of Labour</brief_title>
  <acronym>CONDISOX</acronym>
  <official_title>Continued Versus Discontinued Oxytocin Stimulation of Labour in a Double-blind Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Randers Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kolding Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herning Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The proposed study will investigate the effect of Syntocinon® (synthetic oxytocin) to induce&#xD;
      labour. The hypothesis to be studied is that once the active phase of labour has commenced,&#xD;
      Syntocinon® can be discontinued and the labour process will continue.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Double-blind randomised controlled multicentre trial&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      Aarhus University Hospital, Denmark and Regional Hospital of Randers, Denmark&#xD;
&#xD;
      Population:&#xD;
&#xD;
      1200 women (600 in each group) stimulated in the latent phase of labour with oxytocin for&#xD;
      induction&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The Syntocinon® infusion will be replaced with either continuous isotonic saline (placebo) or&#xD;
      Syntocinon® infusion (control group), when the active phase of labour is reached.&#xD;
&#xD;
      Main outcome measures:&#xD;
&#xD;
      Caesarean section (primary outcome), tachysystole, neonatal asphyxia, birth experience&#xD;
&#xD;
      Perspective:&#xD;
&#xD;
      Syntocinon® is on the list high-alert medications and associated with complications for&#xD;
      mother and child during labour. Reducing the duration of stimulation during labour may lower&#xD;
      the number of asphyxial sequelae and the number of caesarean sections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomisation:&#xD;
&#xD;
      When the orificium ≥6 cm, regular painful contractions (≥3 per 10 minutes) and rupture of&#xD;
      membranes participants will be randomised in a 1:1 ratio to either the control (continued&#xD;
      Syntocinon®) or intervention (discontinued Syntocinon®) group using an Internet-based&#xD;
      randomisation programme. The randomisation can only be performed when the woman consents to&#xD;
      participation. Written consent can be given after the commencement of the Syntocinon®&#xD;
      infusion, provided the woman previously has received sufficient information for her to give&#xD;
      properly informed consent. Random block-sizes of 8 are used, and the participants will be&#xD;
      stratified by site (Aarhus University Hospital, Randers Regional Hospital, Aalborg University&#xD;
      hospital, or Sygehus Lillebælt Kolding), parity (nulliparous or parous) and indication for&#xD;
      Syntocinon® infusion (induction or induction due to premature rupture of membranes).&#xD;
&#xD;
      The randomisation number corresponds to number of the project medicine (ampoule). The&#xD;
      personnel of the delivery ward will administer the ampoules according to existing guidelines&#xD;
      concerning medicine administration&#xD;
&#xD;
      Oxytocin stimulation protocol:&#xD;
&#xD;
      Existing national procedures prior to stimulation will be followed, including use of the&#xD;
      existing checklists. No further examination will be done prior to inclusion and stimulation,&#xD;
      no blood samples nor ECG to identify e.g. unknown QT-syndrome will be performed as this is&#xD;
      never performed as a standard procedure prior to induction.&#xD;
&#xD;
      Latent phase: Stimulation will be given according to national DSOG guidelines7. Initially 20&#xD;
      ml/hour of 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl. The dose rate will be increased&#xD;
      every 20 minutes by 20 ml/hour until appropriate uterine activity of 3-5 contractions per 10&#xD;
      minutes is achieved. The maximum allowed dose rate 180 ml/hour for induction of labour.&#xD;
&#xD;
      Active phase: The woman will be included in the study, when the active phase of labour is&#xD;
      established (cervical dilatation ≥ 6 cm, ≥3 contractions per 10 minutes, and rupture of&#xD;
      membranes). Randomisation is performed, and the infusion will be replaced by the trial&#xD;
      solution, which will be either Syntocinon® at the same concentration, or a placebo infusion&#xD;
      which will not contain Syntocinon®:&#xD;
&#xD;
        1. Control group; 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl infusion&#xD;
&#xD;
        2. Intervention group; 1ml 0,9% NaCl diluted in 1000ml 0,9% NaCl infusion. The infusion&#xD;
           will be continued to achieve uterine activity of 3-5 contractions per 10 minutes.&#xD;
           Maximum allowed dose is 180 ml/hour for induction. The procedure for administration of&#xD;
           the trial solution is identical with the existing procedure.&#xD;
&#xD;
      Complications:&#xD;
&#xD;
      The infusion will be reduced or discontinued at any point of labour, if the following occur:&#xD;
&#xD;
        -  Hyperstimulation (&gt;5 contractions per 10 minutes and non-reassuring CTG13). A management&#xD;
           algorithm for this situation is made.&#xD;
&#xD;
        -  Uterine contractions lasting 2 minutes or more&#xD;
&#xD;
        -  Non-reassuring CTG (recurrent variable decelerations, fetal tachycardia or bradycardia,&#xD;
           minimal to absent baseline variability, late decelerations)&#xD;
&#xD;
        -  Suspicion of uterine rupture These conditions will be managed according to the&#xD;
           guidelines of the local delivery wards.&#xD;
&#xD;
      Dystocia:&#xD;
&#xD;
      If there is failure to progress, defined as less than two cm dilation over 4 hours despite&#xD;
      apparently adequate contractions and/or maximal infusion rates (Syntocinon® or placebo), the&#xD;
      project medicine will be replaced with open-labelled Syntocinon® infusion. Stimulation will&#xD;
      be given according to national DSOG guidelines7. Initially 20 ml/hour of 10 IE Syntocinon®&#xD;
      diluted in 1000 ml 0,9% NaCl. The dose rate will be increased every 20 minutes by 20 ml/hour&#xD;
      until appropriate uterine activity of 3-5 contractions per 10 minutes is achieved. The&#xD;
      maximum allowed dose rate is180 ml/hour for induction.&#xD;
&#xD;
      Woman receiving open-labelled Syntocinon® infusion for 4 hours and continuous failure to&#xD;
      progress: Consider caesarean section.&#xD;
&#xD;
      Unconcealment The primary investigator or a nominated deputy will at all time be able to&#xD;
      break the randomisation code and reveal the allocation group, if needed. The Internet Based&#xD;
      Randomisation Programme will provide the primary investigator or a nominated deputy with this&#xD;
      possibility. (A 24/7 availability of the allocation group is thereby provided).&#xD;
&#xD;
      Side effects and risks:&#xD;
&#xD;
      Persistent failure to progress can be expected in 8-46% of the participants in the placebo&#xD;
      group versus 3-17% in the control group. 3 4 5 6 Based on data from the pilot study, the risk&#xD;
      of caesarean section is expected to be 15% in the placebo group versus 22% in the control&#xD;
      group. According to the pilot study and previous studies 3 4 5 6, the maternal and neonatal&#xD;
      complications in the placebo group are expected to be lower than in the control group.&#xD;
&#xD;
      All participants are monitored with continuous electronic fetal heart rate monitoring during&#xD;
      labour to detect complications such as uterine tachysystole and non-reassuring/pathological&#xD;
      fetal heart rate, in accordance with national guidelines.&#xD;
&#xD;
      The personnel of the delivery ward are responsible for registering of adverse reactions and&#xD;
      adverse events.&#xD;
&#xD;
      Following adverse reactions and event will be registered immediately in the electronic&#xD;
      medical journal of the patient:&#xD;
&#xD;
        -  Cesarean delivery&#xD;
&#xD;
        -  Postpartum hemorrhage &gt;500 ml&#xD;
&#xD;
        -  Manual placenta removal&#xD;
&#xD;
        -  Rupture of the anale sphincter&#xD;
&#xD;
        -  Urine retention&#xD;
&#xD;
        -  Neonatal: pH &lt;7,10 and/or Apgar score ≤ 6 at 5 minutes&#xD;
&#xD;
      Following serious adverse reactions and adverse events will be also registered immediately in&#xD;
      the electronic medical journal of the patient:&#xD;
&#xD;
        -  Intrauterine dead during labour&#xD;
&#xD;
        -  Maternal amniotic fluid emboli or thromboembolic event&#xD;
&#xD;
        -  Maternal cardiac arrest&#xD;
&#xD;
        -  Maternal Pulmonary edema&#xD;
&#xD;
        -  Uterine rupture The women will be followed for at least 3-6 hours postpartum&#xD;
           (termination of project medicine) according current practice on the delivery ward.&#xD;
&#xD;
      The product resume of Syntocinon® will be used as reference to determine whether a Serious&#xD;
      Adverse Reaction is expected or unexpected. Primary investigator or a nominated deputy will&#xD;
      go through the participants medical file 7-30 days postpartum during data management and&#xD;
      Primary investigator will ensure that all relevant information about suspected serious&#xD;
      unexpected adverse reactions that are fatal or life-threatening is recorded and reported as&#xD;
      soon as possible to the competent authorities concerned, and to the Ethics Committee, and in&#xD;
      any case no later than seven days after the knowledge such a case, and that relevant&#xD;
      follow-up information is subsequently communicated within an additional eight days.&#xD;
&#xD;
      Primary investigator will report to the competent authorities concerned and to the Ethics&#xD;
      Committee concerned all other suspected unexpected serious adverse reactions as soon as&#xD;
      possible but within a maximum of 15 days of first knowledge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caesarean section</measure>
    <time_frame>labour</time_frame>
    <description>Frequency of acute performed caesarean sections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Instrumental delivery</measure>
    <time_frame>0-48 hours</time_frame>
    <description>use of vacuum extraction or forceps for delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth experience</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Childbirth Experience Questionaire (CEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding</measure>
    <time_frame>0-6months</time_frame>
    <description>Time to established feeding and duration of exclusive breastfeeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the active phase of labour</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Maternal outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of labour</measure>
    <time_frame>0-48 hours</time_frame>
    <description>(from initiation time of stimulation with Syntocinon until delivery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine tachysystoli</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Parturition will be monitored with continous CTG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine hyperstimulation</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Parturition will be monitored with continous CTG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of epidural analgesia</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and duration of oxytocin infusion</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of episiotomy</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rupture of the anal sphincter</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine rupture</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of blood loss at delivery and postpartum</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for evacuation of retained products of conception</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal use of antibiotics during labour</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal readmission</measure>
    <time_frame>0-168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention of urine</measure>
    <time_frame>0-48 hours</time_frame>
    <description>requiring catheterisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal explorations</measure>
    <time_frame>0-48 hours</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiotocogram (CTG) classification</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Parturition will be monitored with continous CTG. Suspicious, pathologic or terminal CTG will be registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal scalp pH values or Fetal scalp lactate</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score at 1 and 5 minutes</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical cord arterial pH</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal use of antibiotics - postpartum</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hyperbilirubinaemia</measure>
    <time_frame>0-48 hours</time_frame>
    <description>High values of bilirubinaemi, which leads to treatment, will be registered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal admission</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Admission in Neonatal Intensive Care Unit (NICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for resuscitation/ventilation of the newborn</measure>
    <time_frame>0-48 hours</time_frame>
    <description>(bag, mask, CPAP, and/or intubation, time to onset of spontaneous ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal death</measure>
    <time_frame>0-7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of birth of placenta</measure>
    <time_frame>0-2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of maternal readmission</measure>
    <time_frame>0-7 days</time_frame>
    <description>Suspected infection, Endometritis proven with culture, Urinary tract infection treated with antibiotics, Wound infection treated with abtibiotics, Bowel obstruction, Pneumonia, Trombo-embolic complications, Eclampsia, HELLP, Admission due to child, no maternal reason</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Adverse Reaction to Oxytocin</condition>
  <arm_group>
    <arm_group_label>Continued group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recieve routine treatment with oxytocin according to the danish national guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>discontinued group (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.</description>
    <arm_group_label>Continued group</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.</description>
    <arm_group_label>discontinued group (placebo)</arm_group_label>
    <other_name>Isotonic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women stimulated with Syntocinon® infusion for induction of labour (with or without&#xD;
             cervical priming by prostaglandin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to read and understand the Danish language or to give informed consent&#xD;
&#xD;
          -  Cervical dilatation &gt; 4 cm&#xD;
&#xD;
          -  Non-cephalic presentation&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon®&#xD;
             initiation&#xD;
&#xD;
          -  Fetal weight estimation &gt; 4500 g (clinical or ultrasonic)&#xD;
&#xD;
          -  Subject declines participation&#xD;
&#xD;
          -  Gestational age less than 37 completed weeks&#xD;
&#xD;
        Definition: Stimulation with Syntocinon® following Premature Rupture of membranes (PROM) is&#xD;
        induction of labour if there is no cervical change prior to starting the infusion, whereas&#xD;
        stimulation with Syntocinon after PROM but following the establishment of significant&#xD;
        cervical change is augmentation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Uldbjerg, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pinar Bor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regionalhospital Randers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Glavind, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regionalhospital Randers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Steer, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College, London, England</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>AArhus</city>
        <state>Aarhus N</state>
        <zip>8210</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællandshospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus LIllebælt</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Amsterdam-Zuidoost</state>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.condisox.dk</url>
    <description>project webpage with information for participants and personel</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Active phase of labour</keyword>
  <keyword>Discontinuation</keyword>
  <keyword>Caesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The trial is GCP monitored by the GCP unit of Aarhus University Hospital, Odense University Hospital, Copenhagen University and The GCP unit at the AMC&#xD;
Members of the Data Monitoring Committee:&#xD;
Chair: Lone Krebs (Obstetrician) Member: Gorm Greisen (Pediatrician) Member: Martin Johansen (Statistician)&#xD;
Members of the Trial Steering Committee:&#xD;
Chair: Jim Thornton Member: Thomas bergholt Member: Jens Fuglsang Member: Wessel Ganzevoort</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

